论文部分内容阅读
目的:探讨米非司酮联合血府逐瘀胶囊治疗子宫肌瘤的临床效果及安全性。方法:选择2012年6月—2014年6月我院接诊的60例子宫肌瘤患者进行研究,随机分为观察组和对照组。观察组30例,采用米非司酮联合血府逐瘀胶囊治疗。对照组30例,采用米非司酮。比较两组患者的子宫体积及子宫肌瘤的体积、激素含量(LH、FSH、P、E2)、治疗效果及不良反应(恶心,头痛,乏力)。结果:治疗后,观察组患者与对照组患者子宫的体积相比有统计学差异,观察组小于对照组(t=9.3029,P=0.0003);观察组患者的子宫肌瘤的体积小于对照组患者,两者相比有统计学差异(t=3.8804,P<0.0001);观察组患者的LH、FSH、P、E2含量均小于对照组患者,两者相比有统计学差异(P<0.05);观察组的治疗效果优于对照组,两者相比有统计学差异(u=2.4591,P=0.0139);不良反应比较中,观察组与对照组的术后头痛发生比率为0.00%和13.33%,两者相比有统计学差异(χ2=4.2857,P=0.0384);观察组与对照组的不良反应总的发生比率为6.67%和36.67%,两者相比有统计学差异(χ2=7.9542,P=0.0048)。结论:米非司酮联合血府逐瘀胶囊治疗子宫肌瘤的临床疗效良好,安全性较高,预后良好,值得临床推广。
Objective: To investigate the clinical effect and safety of mifepristone combined with Xuefuzhuyu capsule in the treatment of uterine fibroids. Methods: Sixty patients with uterine fibroids admitted from June 2012 to June 2014 in our hospital were selected and randomly divided into observation group and control group. The observation group of 30 cases, the use of mifepristone combined Xuefu Zhuyu capsule treatment. Control group of 30 cases, the use of mifepristone. The volume of uterine fibroids and the volume of uterine fibroids, hormones (LH, FSH, P, E2), therapeutic effects and adverse reactions (nausea, headache, fatigue) were compared between the two groups. Results: The volume of uterine fibroids in the observation group was significantly lower than that in the control group (t = 9.3029, P = 0.0003); the volume of the uterine fibroids in the observation group was smaller than that in the control group (T = 3.8804, P <0.0001). The contents of LH, FSH, P and E2 in the observation group were significantly lower than those in the control group (P <0.05) (U = 2.4591, P = 0.0139). The incidence of postoperative headache in the observation group and the control group was 0.00% and 13.33, respectively, compared with the control group (u = 2.4591, P = 0.0139) %, The difference between the two groups was statistically significant (χ2 = 4.2857, P = 0.0384). The total incidence of adverse reactions between the observation group and the control group was 6.67% and 36.67%, respectively (χ2 = 7.9542, P = 0.0048). Conclusion: The clinical efficacy of mifepristone combined with Xuefuzhuyu capsule in treating uterine fibroids is good, with high safety and good prognosis, which is worthy of clinical promotion.